The drugmakers reported that their bapineuzumab compound failed to meet two primary endpoints and, consequently, they decided to discontinue additional Phase III research planned, although follow-up evaluations and final data analyses will be conducted ( back story).

FORBES: Lilly's Big Alzheimer's Bet: Will It Pay Off?

The companies decided to end the program for developing the compound, called Dimebon, after it failed to meet two primary endpoints in a phase 3 trial studying its use with the existing treatment Aricept in patients with mild-to-moderate Alzheimer's.

WSJ: Medivation, Pfizer Alzheimer's Drug Fails to Meet Study Goals